BRAF and melanoma: As RTKs were found associated with resistance to MAPK inhibition, phenotype switch, invasion, metastases and relapses (4–7), targeting RTKs was considered of particular importance in melanoma, especially in the non-BRAF mutant melanoma subgroup.